Literature DB >> 15629614

Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.

Heon Joo Park1, Ki-Jung Ahn, Seung-Do Ahn, Eunkyung Choi, Sang Wook Lee, Brent Williams, Eun Jung Kim, Robert Griffin, Erik A Bey, William G Bornmann, Jinming Gao, Heon Jin Park, David A Boothman, Chang W Song.   

Abstract

PURPOSE: To reveal the interaction between beta-lapachone (beta-lap) and ionizing radiation (IR) in causing clonogenic death in cancer cells and to elucidate the potential usefulness of beta-lap treatment in combination with radiotherapy of cancer. METHODS AND MATERIALS: FSaII tumor cells of C3H mice were used. The cytotoxicity of beta-lap alone or in combination with IR in vitro was determined using clonogenic survival assay method. The IR-induced changes in the expression and the enzymatic activity of NAD(P)H:quinone oxidoreductase (NQO1), a mediator of beta-lap cytotoxicity, were elucidated and the relationship between the NQO1 level and the sensitivity of cells to beta-lap was investigated. The combined effect of IR and beta-lap to suppress tumor growth was studied using FSaII tumors grown subcutaneously in the thigh of C3H mice.
RESULTS: beta-Lap caused clonogenic death of FSaII tumor cells in vitro in a dose- and time-dependent manner. When cells were treated first with beta-lap and then exposed to IR in vitro, the resultant cell death was only additive. On the contrary, exposing cells to IR at 2.5 Gy first and then treating the cells with beta-lap killed the cells in a synergistic manner. Importantly, the 2.5 Gy cells were sensitive to beta-lap as long as 10 h after irradiation, which was long after the sublethal radiation damage was repaired. Irradiation of FSaII cells in vitro with 2.5 Gy significantly increased the expression and enzymatic activity of NQO1. The growth delay of FSaII tumors caused by an intraperitoneal injection of beta-lap in combination with 20 Gy irradiation of tumor was significantly greater than that caused by beta-lap or 20 Gy irradiation alone.
CONCLUSION: The sensitivity of cells to beta-lap is dependent on NQO1 activity. IR caused a long-lasting increase in NQO1 activity in cancer cells, thereby sensitizing cells to beta-lap and treatment of experimental mouse tumors with IR and beta-lap suppressed tumor growth in a synergistic manner. The combination of beta-lap and radiotherapy is a potentially effective regimen for the treatment of human cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15629614     DOI: 10.1016/j.ijrobp.2004.09.018

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   8.013


  19 in total

1.  Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species.

Authors:  Alycen P Lundberg; Joshua M Francis; Malgorzata Pajak; Elizabeth I Parkinson; Kathryn L Wycislo; Thomas J Rosol; Megan E Brown; Cheryl A London; Levent Dirikolu; Paul J Hergenrother; Timothy M Fan
Journal:  Invest New Drugs       Date:  2016-12-14       Impact factor: 3.850

Review 2.  Phytotherapy and Nutritional Supplements on Breast Cancer.

Authors:  C M Lopes; A Dourado; R Oliveira
Journal:  Biomed Res Int       Date:  2017-08-06       Impact factor: 3.411

3.  Synergistic effect of ionizing radiation and beta-Lapachone against RKO human colon adenocarcinoma cells.

Authors:  Eun Jung Kim; In-Mi Ji; Ki-Jung Ahn; Eun Kyung Choi; Heon-Jin Park; Byung Uk Lim; Chang W Song; Heon Joo Park
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

4.  One-pot, sequential four-component synthesis of benzo[c]pyrano[3,2-a]phenazine, bis-benzo[c]pyrano[3,2-a]phenazine and oxospiro benzo[c]pyrano[3,2-a]phenazine derivatives using 1,4-diazabicyclo[2.2.2]octane (DABCO) as an efficient and reusable solid base catalyst.

Authors:  Alireza Hasaninejad; Somayeh Firoozi
Journal:  Mol Divers       Date:  2013-05-12       Impact factor: 2.943

5.  Comparison of the cytotoxic effect of lapachol, alpha-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells.

Authors:  Eduardo J S Salustiano; Chaquip D Netto; Renata F Fernandes; Alcides J M da Silva; Thiago S Bacelar; Carolina P Castro; Camilla D Buarque; Raquel C Maia; Vivian M Rumjanek; Paulo R R Costa
Journal:  Invest New Drugs       Date:  2009-03-04       Impact factor: 3.850

6.  β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.

Authors:  Moon-Taek Park; Min-Jeong Song; Hyemi Lee; Eun-Taex Oh; Bo-Hwa Choi; Seong-Yun Jeong; Eun-Kyung Choi; Heon Joo Park
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.752

7.  Medicinal plants used as antitumor agents in Brazil: an ethnobotanical approach.

Authors:  Joabe Gomes de Melo; Ariane Gaspar Santos; Elba Lúcia Cavalcanti de Amorim; Silene Carneiro do Nascimento; Ulysses Paulino de Albuquerque
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-08       Impact factor: 2.629

8.  Enhancement of radiation effect using beta-lapachone and underlying mechanism.

Authors:  Ki Jung Ahn; Hyung Sik Lee; Se Kyung Bai; Chang Won Song
Journal:  Radiat Oncol J       Date:  2013-06-30

9.  An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.

Authors:  Erik A Bey; Melissa S Bentle; Kathryn E Reinicke; Ying Dong; Chin-Rang Yang; Luc Girard; John D Minna; William G Bornmann; Jinming Gao; David A Boothman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-03       Impact factor: 12.779

10.  Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.

Authors:  Eun K Choi; Kaoru Terai; In-Mi Ji; Yeon H Kook; Kyung H Park; Eun T Oh; Robert J Griffin; Byung U Lim; Jin-Seok Kim; Doo S Lee; David A Boothman; Melissa Loren; Chang W Song; Heon Joo Park
Journal:  Neoplasia       Date:  2007-08       Impact factor: 6.218

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.